Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia

We investigated the metabolism and disposition of vornorexant, a novel dual orexin receptor antagonist, in rats and dogs, and clarified in vitro metabolite profiles in humans. Furthermore, we investigated the pharmacokinetics of active metabolites in rats and dogs and their CNS distribution in rats...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacology research & perspectives Vol. 12; no. 2; pp. e1183 - n/a
Main Authors:	Konno, Yoshihiro, Kamigaso, Shunsuke, Toki, Hidetoh, Terasaka, Shuichi, Hikichi, Hirohiko, Endo, Hiromi, Yamaguchi, Jun‐Ichi, Mizuno‐Yasuhira, Akiko
Format:	Journal Article
Language:	English
Published:	United States John Wiley & Sons, Inc 01-04-2024 Wiley
Subjects:	Animal cognition Animals Benzodiazepines Chromatography disposition Dogs Drug dosages FDA approval half‐life Humans Insomnia Investigations Mass spectrometry Metabolism Metabolites Oral administration orexin Orexin Receptor Antagonists Orexins Organic Chemicals pharmacokinetic Pharmacokinetics Plasma Prescription drugs Rats Rats, Sprague-Dawley Scientific imaging Sleep Sleep Initiation and Maintenance Disorders TS‐142 Urine vornorexant United States > US Japan disposition metabolism orexin TS-142 pharmacokinetic vornorexant half-life
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!